Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.
- DOI
- 10.1136/jitc-2023-007444
- Published
- 2023 Oct
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2023-007444,
title = {Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.},
author = {Park J and Lee JB and Lim MC and Kim BG and Kim JW and Kim S and Choi CH and Kim HS and Park SY and Lee JY and KGOG investigators},
year = {2023},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2023-007444},
url = {https://doi.org/10.1136/jitc-2023-007444}
}RIS
TY - JOUR TI - Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D. AU - Park J AU - Lee JB AU - Lim MC AU - Kim BG AU - Kim JW AU - Kim S AU - Choi CH AU - Kim HS AU - Park SY AU - Lee JY AU - KGOG investigators PY - 2023 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2023-007444 UR - https://doi.org/10.1136/jitc-2023-007444 ER -
APA
J, P., JB, L., MC, L., BG, K., JW, K., S, K., CH, C., HS, K., SY, P., JY, L., & investigators, K. (2023). Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2023-007444
Source records
- pubmed · retrieved 2026-09-26T16:43:32.846Z